Category Archives: Eczema

Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.

Eylea has powered much of the company's explosive growth since late 2011, but sales growth in the United States has slowed in recent quarters as the market saturates and competition heats up.

Regeneron said on Thursday it expected single-digit percentage increase in U.S. net Eylea sales in 2017, while Wall Street is expecting an 11.3-12.9 percent rise, said Evercore ISI's Mark Schoenebaum.

Indicating the shift, the company said on a post-earnings call that this is the last year it will provide a separate forecast for the eye drug.

Regeneron is betting on two key treatments - Dupixent for eczema and Sarilumab for rheumatoid arthritis - to diversify its revenue stream.

A U.S. regulatory decision on Dupixent is expected by March, while the company hopes to resubmit a marketing application for sarilumab this quarter.

Reimbursement discussions for Dupixent are encouraging, Schleifer said on the call.

Schleifer also underscored Regeneron's practice of not increasing Eylea prices, bucking the industry trend of raising prices on drugs twice a year, often by double digit percentages.

"Price increases are nice, but if you cannot get them you better be able to innovate and that is our sweet spot," he said.

Other drugmakers, including AbbVie and Allergan, have responded to intense criticism over the high price of prescription medicines by vowing to take one increase a year of less than 10 percent.

Regeneron's shares rose as much as nearly 4 percent to $366.95.

PRALUENT WEIGHS

Tepid sales of Regeneron and Sanofi SA's cholesterol-fighter Praluent and lower-than-expected collaboration revenue led to a narrow miss on quarterly revenue.

Praluent - a potent but expensive injection - is yet to unlock its blockbuster potential as health insurers await evidence that the drug can reduce heart attacks.

Amgen Inc has already announced positive heart data on its rival drug Repatha, while Regeneron's trial results are expected later this year.

Global Praluent sales were $41 million, well under analysts' estimates of $57 million, and the $58 million Repatha generated.

Regeneron and Sanofi suffered a huge setback in January after a federal judge banned Praluent sales, finding it infringed patents held by Amgen.

But concerns were allayed on Wednesday, after a U.S. appeals court ruled that the companies can continue selling the drug, while they appeal the permanent injunction.

Excluding items, Regeneron earned $3.04 per share, edging past the average analysts' estimate by 1 cent, according to Thomson Reuters I/B/E/S.

Total revenue rose 11.7 percent to $1.23 billion, but missed estimates of $1.30 billion.

(Reporting by Divya Grover and Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)

TORONTO, Canada A leading drugmaker ramped up its lobbying in Canada fivefold last year, urging government officials to enact a rule that would give it an effective monopoly on long-acting narcotic painkillers.

SHANGHAI Staff at two Chinese hospitals have been punished after their failure to follow proper medical procedures caused 14 patients to be infected with HIV and hepatitis B, state media reported on Friday.

STOCKHOLM Eight countries have joined an initiative to raise millions of dollars to replace shortfalls caused by President Donald Trump's ban on U.S.-funded groups around the world providing information on abortion, Sweden's deputy prime minister said.

Read more:
Regeneron pins hope on eczema drug as Eylea sales slow - Reuters

One in 12 adults are diagnosed with the condition, while one in five kids have to endure the pain of regular flare-ups

It is painful, distracting and can irritate to the point of despair.

One in 12 adults are forced to endure the misery of eczema and in kids the condition is even more common, affecting one in five youngsters.

We reveal more about the skin condition, what causes it and how sufferers can ease their symptoms.

Getty Images

Also known as dermatitis, eczema is a common dry skin condition.

Though common it is rare for two sufferers to experience the same symptoms and discomfort. It is a highly varied condition and comes in many forms.

Despite the fact it causes, often unbearable, itching, the condition is not contagious, and so cannot be caught from someone suffering a flare-up.

In mild cases, a persons skin is dry, scaly, red and itchy.

But, in more severe cases there can be weeping, crusting and bleeding sores as a result.

The constant compulsion to itch can leave the skin split and bleeding and also leaves it open to infection.

Eczema affects people of all ages, but is typically diagnosed in children.

Many young sufferers will grow out of their condition as they get older.

But, in many cases flare ups in adulthood can happen.

In the UK one in five children is diagnosed with eczema, while one in 12 adults live with the condition.

Getty Images

Atopic eczema is a genetic condition, which means it is inherited.

Its caused by the interaction of a number of genes and environmental factors.

In most cases there is a family history of the condition, or of other atopic conditions, which include asthma or hayfever.

The skin is the bodys largest organ, providing a strong and effective barrier to protect the body from infections and irritation.

Skin is made up of a thin outer layer, an elastic middle layer, and a fatty layer at the deepest level.

Each layer contains skin cells, water and fats all of which help maintain and protect the skin.

Healthy skin is moisturised by fats, oils and plumped up with adequate water levels.

In eczema sufferers, the skin fails to produce the necessary levels of fats and oils, and it is less able to retain water.

The result is, the bodys protective layer, isnt as good as it could be.

Getty Images

Dry skin is more liable to crack and as a result infections, bugs and germs can get into the cracks.

Many everyday products can aggravate the condition, as some soaps and cleaning products remove oil from a persons skin.

Keeping the skin moisturised using emollients or medical moisturisers is the key to managing all forms of the condition.

In some cases, doctors will prescribe topical steroids to bring aggressive flare ups under control.

Source: National Eczema Society

READ MORE

Girl whose scaly skin oozed and peeled off cures her eczema by going vegan

From meningitis to eczema and ringworm we reveal what your babys RASH means

Seven-year-old lads eczema is so severe that doctors are treating him with CHEMOTHERAPY

Brave psoriasis sufferer shares powerful photograph revealing the scaly skin underneath her perfect make-up

See the original post:
What is eczema, what causes it and how can you treat the painful ... - The Sun

Thursday 09 February 2017 02:39 PM

Bionona sticks to online sales in launch of eczema treatment

By Paul McBeth

Feb. 8 (BusinessDesk) - Bionona has launched its Atopis eczema cream treatment and will stick to online sales as it chases "a couple of million" in sales in the first year.

The cream is the brainchild of chief executive Iona Weir, the biochemist who oversaw the development of the Phloe laxative, and has taken four-to-five years to develop in her garage. The research behind the cream came from her Marsden Fund-backed work on programmed cell death in plants known as apoptosis, and through that time attracted Callaghan Innovation support for its second clinical trial in New Zealand during 2015.

Weir told BusinessDesk she wants Atopis to be the number one eczema product in New Zealand and is also targeting sales in the US in a state-by-state roll-out, starting with Colorado.

"In the States, one-in-ten people in the United States has eczema, so even if we get 1 percent of that market, then that's an incredible sized market," she said.

When asked what kind of sales volume target she wants to hit in the first 12 months, Weir said she was aiming for "at least a couple of million". When Vital Foods launched Phloe in 2007, Weir said it sold out in the first morning and was targeting three million units in the first year.

The company chose to avoid wholesalers and distributors and stick to online sales after her experience with Phloe, which generated half of its sales through online channels.

"We discovered online seemed a much better option," she said. "Why would we lose all that money to wholesalers and distributors if we had a proper online marketing campaign?"

Bionona attracted the backing of former NPT executive chairman Paul Dallimore who used the cream on his own grandchildren and was so impressed that he put money into the first clinical testing in the US three years ago.

The company's New Zealand manufacturing will be done out of a factory in Onehunga, while Douglas Pharmaceuticals will cover its over-the-counter grade creams in the US.

Weir said the company has the ability to scale up quickly, with Dallimore "and some of his mates" putting money into the business, and expects to have about 18 months lead-time before "people try to copy us".

She shied away from raising money from the market after a previous experience with venture capitalists put her off, and decided "this time I'm going to take a slower path and do it all myself before bringing the money in".

"It's taken me three times as long, but it's been much more worthwhile," she said.

(BusinessDesk receives funding to help cover the commercialisation of innovation from Callaghan Innovation.)

(BusinessDesk)

ends

Scoop Media

Independent, Trustworthy New Zealand Business News

The Wellington-based BusinessDesk team led by former Bloomberg Asian top editor Jonathan Underhill and Qantas Award-winning journalist and commentator Pattrick Smellie provides a daily news feed for a serious business audience.

Continued here:
Bionona sticks to online sales in launch of eczema treatment | Scoop ... - Scoop.co.nz (press release)

Review of Moisturizer Efficacy in Eczema Monthly Prescribing Reference (registration) Among patients with eczema, most moisturizers showed some benefit but better results were seen when used with topical active treatment, according to a Cochrane Review. Keeping the skin moisturized is an important part of treating eczema but the ...

Read the original:
Review of Moisturizer Efficacy in Eczema - Monthly Prescribing Reference (registration)

Good news: New medicines coming out will greatly help in the treatment of atopic eczema Child with atopic eczema before (l) and after treatment

Eczema and dermatitis are both terms with the same meaning: inflammation, redness, and itching of the skin. Atopic eczema (a.k.a. atopic dermatitis) is a skin disease. The first sign of eczema tends to be patches of dry or red, itchy skin. Atopic eczema is controlled by a combination of genetic and environmental factors.

Unfortunately, because dermatitis can be so itchy, aggressive scratching can injure the skin and worsen the condition. Sometimes the itch can precede the rash. Some doctors say atopic eczema is the itch that rashes.

Atopic eczema usually begins very early in life as a condition affecting infants or young children, but it can occur at any age. It is most common in infants and young children, and most people who get eczema will have it before they turn five years old. It is rare for eczema to appear for the first time in adults.

Eczema can be more common and problematic in persons of color. In fact, 25 percent of all children of color (and large percentages of other children as well) can be affected by atopic eczema.

Eczema tends to come and go, often without warning. A treatment plan that includes skin care can reduce flare-ups and ease much of the discomfort.

The good news is that there are excellent new treatments for atopic eczema available now and coming out this summer. I will discuss those shortly.

What causes eczema?

Atopic eczema is a genetic condition. It is often seen in patients whose family members have it or other related conditions such as asthma, hay fever or allergic rhinitis. Some patients may have atopic eczema alone or with several or all of these other conditions.

There is emerging evidence that patients with atopic eczema may have a mild disability to repair their skin barrier. Also, excessive bacteria on the skin with bacterial enzymes (proteases) can make eczema worse. These are two important targets in controlling the disease.

Atopic eczema is not contagious. Dry skin, dry weather, perspiration and illness are several things that can cause atopic eczema to get worse.

How can I tell if my child has eczema?

Atopic eczema presents as red, flakey, itchy patches. In children, it commonly appears on the folds of the elbows and knees and on the scalp, forehead and cheeks, but it can be present anywhere. Atopic eczema itches so much that infants commonly rub their cheeks on bed linens or even carpeting for relief.

In extreme cases, a yellow fluid may even weep from the involved areas. Scratching over extended periods of time will cause the skin to become tough and thicken up. This is a common finding in patients with longstanding eczema that has not been completely controlled.

If you think that your child has atopic eczema, visit a board-certified dermatologist to make sure the diagnosis is correct. A dermatologist can often diagnose eczema by examining the patients skin, as well as by asking historically significant questions about a family history of similar skin rashes or asthma or hay fever.

How long will my child have eczema?

In most children, atopic eczema may get better over time, but their skin will always be more sensitive than those without atopic eczema, even as adults.

How is eczema treated?

A dermatologist will create a specific treatment for the patient with atopic eczema. Most treatment plans consist of:

There is no one treatment for atopic eczema. It is important to follow the treatment plan designed by your dermatologist, and the success in adequately managing atopic eczema depends on carefully following the treatment plan. Dermatologists will develop plans that are both safe and effective for long-term use.

In February of 2017, the FDA has approved a new ointment called Crisaborole (Eucrisa) for the treatment of atopic dermatitis. It is an ointment that is applied twice daily to the affected areas.Many patients are seeing remarkable improvements in just one or two weeks.

Over the past 10 years, there has been an explosion of medicines called biologic treatments for psoriasis. A promising new medication from this class is called Dupilumab. This medicine blocks a special protein receptor (interleukin-4) that controls regulatory proteins (interleukin-4 and interleukin-13) that control how certain white blood cells (type 2 helper T-cells)create inflammation in the skin, the hallmark of atopic eczema. This medicine, and others like it, may be available as soon as this summer.

What will the treatment plan include?

Why see a dermatologist?

When a child has atopic eczema, it is a condition that affects the entire family. It takes time away from other siblings and caregivers and can affect performance in school.

As a dermatologist, I like to tell parents atopic eczema is like having asthma of the skin. Just like asthma, it can wax and wane and have certain triggers. Just like asthma, it is a lifelong condition that needs attention but over time may improve.

With so much information out there, much of it misleading or downright inaccurate, it can be challenging for a parent to know exactly what to do. Dermatologists specialize in treating skin conditions and can help parents make the best-informed decisions for their children.

A dermatologist can develop a specific treatment plan for the atopic eczema patient. With new medicines being approved and released, in combination with the other classic treatments listed above, we will be able to treat atopic eczema better than ever before.

Research has shown that parents who develop a good relationship with their dermatologist and follow a designed treatment plan will have the most success in treating their childs atopic eczema over time.

Charles E. Crutchfield III, MD is a board certified dermatologist and Clinical Professor of Dermatology at the University of Minnesota Medical School.He also has a private practice in Eagan, MN.He received his M.D. and Masters Degree in Molecular Biology and Genomics from the Mayo Clinic. He has been selected as one of the top 10 dermatologists in the United States byBlack Enterprise magazine.Dr. Crutchfield was recognized by Minnesota Medicine as one of the 100 Most Influential Healthcare Leaders in Minnesota. He is the team dermatologist for the Minnesota Twins, Vikings, Timberwolves, Wild and Lynx. Dr. Crutchfield is an active member of both the American and National Medical Associations.

Originally posted here:
Atopic eczema is like an 'asthma of the skin' - MSR News Online

Bionona has launched its Atopis eczema cream treatment and will stick to online strategy as it chases "a couple of million" in sales in the first year.

The cream is the brainchild of chief executive Iona Weir, the biochemist who oversaw the development of the Phloe laxative and has taken four to five years to develop in her garage.

The research behind the cream came from her Marsden Fund-backed work on programmed cell death in plants known as apoptosis, and through that time attracted Callaghan Innovation support for its second clinical trial in New Zealand during 2015.

Ms Weir wants Atopis to be the number one eczema product in New Zealand and is also targeting sales in the US in a state-by-state roll-out, starting with Colorado.

"In the states, one in 10 people has eczema, so even if we get 1% of that market, then that's an incredible sized market," she said.

When asked what kind of sales volume target she wants to hit in the first 12 months, Ms Weir says she is aiming for "at least a couple of million".

When Vital Foods launched Phloe in 2007, Ms Weir says it sold out in the first morning and was targeting three million units in the first year.

The company chose to avoid wholesalers and distributors and stick to online sales after her experience with Phloe, which generated half of its sales through online channels.

"We discovered online seemed a much better option," she said. "Why would we lose all that money to wholesalers and distributors if we had a proper online marketing campaign?"

Bionona attracted the backing of former NPT executive chairman Paul Dallimore who used the cream on his own grandchildren and was so impressed that he put money into the first clinical testing in the US three years ago.

The company's New Zealand manufacturing will be done in an Onehunga factory, while Douglas Pharmaceuticals will cover its over the counter grade creams in the US.

Ms Weir says the company has the ability to scale up quickly, with Mr Dallimore "and some of his mates" putting money into the business, and expects to have about 18 months lead-time before "people try to copy us."

She shied away from raising money from the market after a previous experience with venture capitalists put her off, and decided "this time I'm going to take a slower path and do it all myself before bringing the money in."

"It's taken me three times as long, but it's been much more worthwhile," she says.

(BusinessDesk receives funding to help cover the commercialisation of innovation from Callaghan Innovation.)

(BusinessDesk)

Go here to see the original:
Bionona sticks to online sales in launch of eczema treatment - The National Business Review

Infants with eczema are three times more likely to develop tooth decay at 2 and 3 years of age, experts warn. The good news is that tooth decay is highly preventable.

Our latest findings will give parents and caregivers of babies with eczema early warning of increased risk of developing tooth decay in toddlers, says Stephen Hsu, associate professor of dentistry at the National University of Singapore.

Regular dental check-ups can then be conducted to help minimize the incidence of tooth decay in these children.

Tooth decay is a common childhood diseasea 2009 study showed that four in 10 preschool children in Singapore suffered from tooth decay. The skin condition eczema affects one in five children attending school in Singapore.

For the study, published in theJournal of Allergy and Clinical Immunology, researchers recruited pregnant women in their first trimester as part of the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) program.

Established in 2009, GUSTO is a nationwide long-term study of pregnant Singaporean mothers and their children, and to date has recruited more than 1,200 Singaporean families.

During the childs first year, at the ages of 3, 6 and 12 months, parents were interviewed to identify babies with eczema. Infants with eczema were given skin prick testing to assess their sensitivity to common allergens.

The findings show that infants who had eczema and were sensitive to common allergens were 3.29 times and 3.09 times more likely to experience tooth decay when they were two and three years of age respectively, compared to infants without eczema.

The researchers say that structural defects during tissue development could be a possible reason for the connection.

Theyre now conducting genetic analysis to confirm the mechanism and explorethe link between tooth decay and other childhood diseases potentially affected by ectodermal defects.

Follow Knowridge Science Report onFacebook.

News source:National University of Singapore. The content is edited for length and style purposes. Figure legend: This Knowridge.com image is for illustrative purposes only.

Read the rest here:
Babies with eczema may have tooth decay later - Knowridge Science Report

PISCATAWAY, N.J., Feb. 6, 2017 /PRNewswire/ --Eczema in childhoodis a critical issue, with as many as one out of every three kids suffering from this chronic skin condition. Beyond the constant itching, irritation and distraction caused by this silent skin disease, many children also endure bullying, teasing and a major hit to their self-esteem due to the inflamed, rough patches.

In a new video, PuraCap Pharmaceutical explores the effects of childhood eczema and how parents and kids can find relief.

Fundamental to the disease is impairment to the skin barrier, the protective function that is responsible for the integrity of the skin and the regulation of water loss. Eczema can be triggered especially this time of year by dry, heated indoor environments.

When left untreated, eczema, which may begin during infancy, continues on into the child's teenage years and often lasts into adulthood. In fact, according to a survey by PuraCap Pharmaceutical, six in 10 adults report lower confidence as a result of eczema.

In order to effectively manage eczema symptoms, dermatologists agree that repairing the skin barrier is key to successful treatment; however, 50 percent of consumers are not familiar with skin barrier repair products. In fact, the number one treatment used to combat eczema is over-the-counter moisturizers, which may grant temporary relief, but don't provide lasting hydration or any repair.

EpiCeram Controlled Release Skin Barrier Emulsion can help restore skin to its natural healthy condition. The FDA-approved cream contains all of the essentials for total skin barrier repair to help relieve itching, dryness and redness. Formulated to help keep the skin at a healthy pH of 5, EpiCeram works to repair the skin's barrier and improve the protective properties of the skin.

"Eczema-afflicted skin has fundamental issues with the protective skin barrier," shares Dr. Jessie Cheung, Board-certified Dermatologist in Illinois. "EpiCeram replenishes the lost lipids in the skin with a unique blend of ceramides, cholesterol, and free fatty acids to help rebuild the skin barrier and bind moisture in the skin while keeping irritants out."

With a unique controlled-release technology, EpiCeram delivers 24-hour barrier repair benefits with just twice-daily application.

EpiCeram is only available by prescription. Please consult your physician to find out how it can help manage your eczema.

For more informationor full prescribing information go tohttp://epiceram-us.com

About PuraCap Pharmaceutical LLCPuraCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing and distribution bringing,high quality products & services to their customers. PuraCap's corporate structure supports a two-pronged approach for global growth in the areas of prescription brands and OTC and private label brands (PuraCap Pharmaceutical LLC) as well as prescription generics (PuraCap Laboratories LLC). Go to http://www.puracap.com for more information.

ContactKELZ PR Sheila - 144832@email4pr.com Melissa - 144832@email4pr.com 646.450.5359

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/below-the-surface-study-finds-eczema-damages-confidence-300402081.html

Continue reading here:
Below the Surface: Study Finds Eczema Damages Confidence - Yahoo Finance

It may be possible to prevent babies from getting eczemaa costly, inflammatory skin disorderjust by applying something as inexpensive as petroleum jelly every day for the first six months of life.

A new study published inJAMA Pediatricsshows that seven common moisturizers could inexpensively prevent eczema in high-risk newborns.

By using the cheapest moisturizer in the study (petroleum jelly), the cost benefit for prophylactic moisturization was only $353 per quality-adjusted life yeara generic measure of disease burden that assesses the monetary value of medical interventions in ones life.

Eczema affects as many as 20 percent of children and costs the US healthcare system as much as $3.8 billion dollars every year.

Previous studies have shown that families caring for a child with the skin disorder can spend as much as 35 percent of their discretionary incomean average of $274 per month.

Its not only terrible for the kids, but also for their families, says Steve Xu, a resident physician in dermatology at Northwestern University Feinberg School of Medicine. Eczema can be devastating.

Beyond the intractable itch, a higher risk of infections, and sleep problems, a child with eczema means missed time from school, missed time from work for parents, and huge out-of-pocket expenses. So if we can prevent that with a cheap moisturizer, we should be doing it.

Early studies from Japan, the US and the UK have suggested that full-body application of moisturizers for six to eight months, beginning within the first few weeks of life, can reduce the risk that eczema will develop.

The new study took that one step further and examined the cost-effectiveness of seven common, over-the-counter moisturizer products, such as petroleum jelly, Aquaphor, Cetaphil, and Aveeno.

Theres an important economic argument to be made here, Xu says. Moisturizers are an important intervention dermatologists use to treat eczema.

They play a big role in getting our patients better. But insurers do not usually cover the cost of moisturizers. Were arguing for their inclusion in health insurance coverage.

While the evidence on prophylactic moisturization is preliminary, Xu says, Were not giving them an oral drug or injecting them with a medication; there is minimal risk.

Were putting Vaseline on these babies to potentially prevent a very devastating disease.

Follow Knowridge Science Report onFacebook.

News source:Northwestern University. The content is edited for length and style purposes. Figure legend: This Knowridge.com image is for illustrative purposes only.

Read the original post:
7 cheap moisturizers can prevent eczema in babies - Knowridge Science Report

Australian children are unnecessarily suffering from prolonged flare-ups of eczema because of "unfounded" concerns about steroid creams, say dermatologists.

Topical corticosteroids (TSC) remain the mainstay treatment for the chronic inflammatory disease of the skin that affects about 30 per cent of Australian and New Zealand children.

However fears and "misinformation" about their possible side effects is "undermining" the advice given by dermatologists to parents with eczema.

Long-term use of topical corticosteroids can lead to skin thinning but if used correctly this can be avoided, says the Australian College of Dermatologists.

'Steroid phobia' needs to stop, says Professor Chris Baker, president of the ACD.

A position statement on the use of corticosteroids, released by the college on Monday, calls for the re-education of health professionals and the community on the "excellent safety record" of these topical medical creams.

"Unfounded concerns about their adverse effects has resulted in 'steroid phobia' and an underutilisation of TSC, leading to unnecessary exacerbations of eczema for children," the statement says.

The recommendation to 'use sparingly' is "nonsensical" and has no value.

"There is no requirement to use sparingly. It is recommended that an ample volume of cream is applied to sufficiently cover the entire affected area," the statement adds.

It's estimated severe eczema costs over $6000 per child per year in direct medical costs, hospital and treatment costs, as well as time off work for caregivers and untold distress for the family unit.

Then there is the unseen impacts on a child.

"Although eczema in itself is not a life-threatening disease, it can certainly have a debilitating effect on a sufferer," said Cheryl Talent, President of the Eczema Association of Australasia.

"Night-time itching can cause sleepless nights and eczema 'flare-ups' can often lead to absenteeism from school. Using moisturiser to prevent the skin from cracking or itching can offer relief, but the most effective treatment for eczema is topical steroids," she said.

"Of course, it is important to seek professional medical advice before using any medication," Ms Talent added.

KEY ADVICE FROM DERMATOLOGISTS

* Apply 1-2 times a day as per the product directions

* Do not use sparingly. Ensure ample volume of cream is applied to sufficiently cover affected area.

* Diluting a strong steroid cream with moisturiser does not reduce its clinical effect.

* There is little difference in clinical effect between 0.5, 1 and 2% hydrocortisone.

See the rest here:
'Steroid phobia' worsening child eczema - NEWS.com.au